title: 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
abstract: A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.
authors: Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
authors: J A
authors: JA
authors: Casas
authors: P A
authors: PA
authors: Saway
authors: I
authors: I
authors: Villarreal
authors: C
authors: C
authors: Nolte
authors: B L
authors: BL
authors: Menajovsky
authors: E E
authors: EE
authors: Escudero
authors: W D
authors: WD
authors: Blackburn
authors: G S
authors: GS
authors: Alarcón
authors: C P
authors: CP
authors: Subauste
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
chemical_list: D005472:Fluorouracil